Literature DB >> 2441993

The role of I-131-MIBG in the diagnosis and therapy of carcinoids.

C A Hoefnagel, F C den Hartog Jager, B G Taal, N G Abeling, E E Engelsman.   

Abstract

The successful use of 131I-MIBG for the diagnosis and treatment of pheochromocytoma and neuroblastoma has led to its application in patients with carcinoid, another neural crest tumor. The present report describes the scintigraphic findings, in correlation with clinical and biochemical parameters, in 20 patients with histologically proven carcinoids. 131I-MIBG total body scintigraphy was positive in 12 and equivocal in 1 of 19 patients with metastases. The necessity of delayed imaging and the possible advantage of single photon emission tomography for the detection of this tumor are emphasized. The results of 131I-MIBG treatment in five patients with progressive carcinoid metastases are discussed. It is concluded that 131I-MIBG has a role in the work up of patients with proven carcinoid and can be used for palliative treatment of this tumor.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2441993     DOI： 10.1007/bf00256489

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


  11 in total

1.  Carcinoid syndrome associated with hyperserotoninemia and normal 5-hydroxyindoleacetic acid excretion.

Authors:  R B DAVIS; J C ROSENBERG
Journal:  Am J Med       Date:  1961-01       Impact factor: 4.965

Review 2.  Pharmacologic and endocrine aspects of carcinoid syndrome.

Authors:  J A Oates; T C Butler
Journal:  Adv Pharmacol       Date:  1967

3.  Scintigraphic imaging of carcinoid tumours with 131I-metaiodobenzylguanidine.

Authors:  M Fischer; D Kamanabroo; H Sonderkamp; T Proske
Journal:  Lancet       Date:  1984-07-21       Impact factor: 79.321

4.  Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine.

Authors:  C A Hoefnagel; P A Voûte; J de Kraker; H R Marcuse
Journal:  J Nucl Med       Date:  1987-03       Impact factor: 10.057

5.  Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Authors:  B Shapiro; J E Copp; J C Sisson; P L Eyre; J Wallis; W H Beierwaltes
Journal:  J Nucl Med       Date:  1985-06       Impact factor: 10.057

6.  Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I]iodobenzylguanidine: concise communication.

Authors:  M D Lynn; B Shapiro; J C Sisson; D P Swanson; T J Mangner; D M Wieland; L J Meyers; J V Glowniak; W H Beierwaltes
Journal:  J Nucl Med       Date:  1984-04       Impact factor: 10.057

7.  Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors.

Authors:  J M Feldman; R A Blinder; K J Lucas; R E Coleman
Journal:  J Nucl Med       Date:  1986-11       Impact factor: 10.057

8.  Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine.

Authors:  C A Hoefnagel; F C Den Hartog Jager; A H Van Gennip; H R Marcuse; B G Taal
Journal:  Clin Nucl Med       Date:  1986-03       Impact factor: 7.794

9.  Scintigraphic localization of pheochromocytoma.

Authors:  J C Sisson; M S Frager; T W Valk; M D Gross; D P Swanson; D M Wieland; M C Tobes; W H Beierwaltes; N W Thompson
Journal:  N Engl J Med       Date:  1981-07-02       Impact factor: 91.245

10.  Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma.

Authors:  C A Hoefnagel; P A Voûte; J de Kraker; H R Marcuse
Journal:  Diagn Imaging Clin Med       Date:  1985
View more
  6 in total

Review 1.  Therapeutic radionuclides in nuclear medicine: current and future prospects.

Authors:  Chai-Hong Yeong; Mu-hua Cheng; Kwan-Hoong Ng
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

2.  Glomerular filtration rate and the kinetics of 123I-metaiodobenzylguanidine.

Authors:  G M Blake; V J Lewington; M A Zivanovic; D M Ackery
Journal:  Eur J Nucl Med       Date:  1989

3.  Somatostatin analogue scintigraphy in carcinoid tumours.

Authors:  D J Kwekkeboom; E P Krenning; W H Bakker; H Y Oei; P P Kooij; S W Lamberts
Journal:  Eur J Nucl Med       Date:  1993-04

Review 4.  Radionuclide therapy revisited.

Authors:  C A Hoefnagel
Journal:  Eur J Nucl Med       Date:  1991

5.  The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.

Authors:  D I Jodrell; A T Irvine; V R McCready; E Woodcraft; I E Smith
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

6.  Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG).

Authors:  A Kuin; M Rutgers; M A van der Valk; J H Beijnen; L A Smets
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.